David R. Gius (born August 23, 1960) is an American physician-scientist [1] the Zell Family Scholar Professor, [2] Women's Cancer Research Program director, and Vice Chair of Translational Research [3] at Northwestern University's Feinberg School of Medicine Department of Radiation Oncology and Pharmacology. His research focuses into the mechanistic connection between aging, cellular and/or mitochondrial metabolism, and carcinogenesis focusing on the Sirtuin gene family. [4]
Gius graduated from the University of Illinois at Chicago in 1983 with an undergraduate degree in chemistry. He completed his Ph.D. at the University of Chicago in 1990, and his M.D. at the Loyola University of Chicago Strich School of Medicine in 1992.
Dr. Gius is Currently a Professor of Radiation Oncology, the Assistant Dean for Research at the Joe R. & Teresa Lozano Long School of Medicine and an Associate Cancer Center Director at the Mays Cancer Center at the University of Health Sciences Center San Antonio (UTHSCSA), San Antonio MD Anderson, San Antonio, TX. He is also the only Radiation Oncologist to serve as an Established Investigator Scholar in Cancer Research as part of the Cancer Prevention Research Institute of Texas (CPRIT) and one of only 60 awardees since the initiation of CPRIT in 2021.
Dr. Gius did his postdoctoral fellowship training in the Howard Hughes Medical Institute at the University of Chicago, until 1993, with Vikas P. Sukhatme and Tom Curran. Afterwards, he moved to St. Louis, MO where he did his residency in Radiation Oncology Resident at the Radiation Oncology Center at Washington University School of Medicine where he was also an Assistant Professor and Residency Director of the Section of Cancer Biology in the Department of Radiation Oncology at Washington University School of Medicine. Between 2001 and 2010 he was the Chief of the Molecular Radiation Oncology Section at the National Cancer Institute (NCI) where he also served as the residency director of NCC Radiation Oncology Residency, clinical director of GYN services in the Center for Cancer Research, and a Principal Investigator at the NCI in Bethesda, MD. In 2005 he became the Associate Program Director of the National Institutes of Health Oxford-Cambridge Graduate Scholars Program that is a Trans-NIH MD/PhD Partnership Program. Prior to his current appointment at UTHSCSA Dr. Gius was a Professor of Radiation Oncology and the Director of the Women's Cancer Program In at the Robert H. Lurie Cancer Center at the Northwestern University Feinberg School of Medicine
Richard G. Pestell is an Australian American oncologist and endocrinologist who is Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. Pestell was appointed an Officer of the Order of Australia in the 2019 Queen's Birthday Honours for distinguished service to medicine and medical education.
NAD-dependent deacetylase sirtuin 2 is an enzyme that in humans is encoded by the SIRT2 gene. SIRT2 is an NAD+ -dependent deacetylase. Studies of this protein have often been divergent, highlighting the dependence of pleiotropic effects of SIRT2 on cellular context. The natural polyphenol resveratrol is known to exert opposite actions on neural cells according to their normal or cancerous status. Similar to other sirtuin family members, SIRT2 displays a ubiquitous distribution. SIRT2 is expressed in a wide range of tissues and organs and has been detected particularly in metabolically relevant tissues, including the brain, muscle, liver, testes, pancreas, kidney, and adipose tissue of mice. Of note, SIRT2 expression is much higher in the brain than all other organs studied, particularly in the cortex, striatum, hippocampus, and spinal cord.
NAD-dependent deacetylase sirtuin-3, mitochondrial also known as SIRT3 is a protein that in humans is encoded by the SIRT3 gene [sirtuin 3 ]. SIRT3 is member of the mammalian sirtuin family of proteins, which are homologs to the yeast Sir2 protein. SIRT3 exhibits NAD+-dependent deacetylase activity.
Yale Cancer Center (YCC) was founded in 1974 as a result of an act of Congress in 1971, which declared the nation's "war on cancer". It is one of a network of 56 Comprehensive Cancer Centers designated by the National Cancer Institute (NCI). Currently directed by Dr. Eric Winer, the Cancer Center brings together the resources of the Yale School of Medicine (YSM), Yale New Haven Hospital (YNHH), and the Yale School of Public Health (YSPH).
Wafik El-Deiry is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University, Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously deputy director of Translational Research at Fox Chase Cancer Center, where he was also co-Leader of the Molecular Therapeutics Program.
Larry Kwak is an American cancer researcher who works at City of Hope in Duarte, California and is the Director of the Toni Stephenson Lymphoma Center at City of Hope. Dr. Kwak formerly worked at the University of Texas MD Anderson Cancer Center. He was included on Time's list of 2010's most influential people.
Professor Minesh P. Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
David Henry Gorski is an American surgical oncologist and professor of surgery at Wayne State University School of Medicine. He specializes in breast cancer surgery at the Karmanos Cancer Institute. Gorski is an outspoken skeptic and critic of alternative medicine and the anti-vaccination movement. A prolific blogger, he writes as Orac at Respectful Insolence, and as himself at Science-Based Medicine where he is the managing editor.
Edith A. Pérez is a Puerto Rican hematologist-oncologist. She is the Serene M. and Frances C. Durling Professor of Medicine at the Mayo Clinic Alix School of Medicine.
Walter "Wally" J. Curran, Jr. is an American radiation oncologist specializing in the treatment of malignant brain tumors and locally advanced lung cancer.
Branimir Ivan "Brandy" Sikic is an American medical doctor and scientist at Stanford University School of Medicine. He is an oncologist and cancer pharmacologist, and has served as a faculty member at Stanford University since 1979. His research spans basic, translational, and clinical research and investigates the mechanisms of drug resistance and the development of new anticancer therapies.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Steven T. Rosen is the Provost and chief scientific officer of the City of Hope National Medical Center in Duarte, California. In addition to directing City of Hope's Comprehensive Cancer Center, Rosen leads the Beckman Research Institute at City of Hope, and the Irell & Manella Graduate School of Biological Sciences. Previously (1989-2014) Rosen was the director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, which was awarded comprehensive cancer center status by the National Cancer Institute (NCI) in 1997.
Maha H. Hussain is the Genevieve E. Teuton Professor of Medicine and deputy director of the Lurie Comprehensive Cancer Center at Northwestern University's Feinberg School of Medicine. She is an oncologist focusing on genitourinary cancers.
Melissa Andrea Simon is an American clinical obstetrician/gynecologist and scientist who focuses on health equity across the lifespan. Simon is founder and director of the Center for Health Equity Transformation (CHET) in the Feinberg School of Medicine at Northwestern University in Chicago, Illinois, and founder of the Chicago Cancer Health Equity Collaborative, a National Cancer Institute comprehensive cancer partnership led by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northeastern Illinois University, and the University of Illinois at Chicago. She is the George H. Gardner, MD Professor of Clinical Gynecology, the Vice-Chair of Clinical Research in the Department of Obstetrics and Gynecology, tenured professor of Obstetrics and Gynecology, Preventive Medicine and Medical Social Sciences at Northwestern University Feinberg School of Medicine, and Associate Director of Community Outreach and Engagement at the Robert H. Lurie Comprehensive Cancer Center.
Christina Messineo Annunziata is an American medical oncologist researching molecular signal transduction in ovarian cancer. She is an investigator in the National Cancer Institute's women's malignancies branch and head of the translational genomics section.
Deborah E. Citrin is an American clinician-scientist researching pre-clinical and clinical testing of radiation modifiers and the mechanisms of normal tissue injury from radiation. She is a senior investigator and deputy director of the National Cancer Institute's Center for Cancer Research.
Everett E. Vokes is an American oncologist. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medical Center. In this role, he pioneered the combination radiation and chemotherapy as first-line treatment for head and neck cancer.
Leonidas C. Platanias is a Greek-American oncologist. He is the Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Jesse, Sara, Andrew, Abigail, Benjamin, and Elizabeth Lurie Professor of Oncology in the Departments of Medicine and Biochemistry and Molecular Genetics.
| International | |
|---|---|
| National | |
| Academics | |
